Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Minerva Neurosciences, Inc. (NASDAQ: NERV).

Full DD Report for NERV

You must become a subscriber to view this report.


Recent News from (NASDAQ: NERV)

Minerva Delays Roluperidone Data, But Remains On Track For Transformational 2019
Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic differentiation (have superior efficacy and safety, serve unmet needs, have limited competition, etc.). I have one model portfolio of my top biotech stocks focused on conviction ideas with in...
Source: SeekingAlpha
Date: November, 08 2018 01:18
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies ...
Source: GlobeNewswire
Date: November, 07 2018 08:30
Minerva Neurosciences' (NERV) CEO Remy Luthringer on Q3 2018 Results - Earnings Call Transcript
Minerva Neurosciences (NERV) Q3 2018 Earnings Conference Call November 5, 2018 8:30 AM Executives William Boni – Vice President-Investor Relations and Corporate Communications Remy Luthringer – Chief Executive Officer Geoff Race – Executive Vice President and...
Source: SeekingAlpha
Date: November, 05 2018 13:39
Microcaps mostly among midday movers
More news on: Datawatch Corporation, JinkoSolar Holding Co., Ltd., Yulong Eco-Materials, , Stocks on the move, Read more ...
Source: SeekingAlpha
Date: November, 05 2018 12:46
Minerva Neurosciences reports Q3 results
Minerva Neurosciences (NASDAQ: NERV ) Q3 results: Revenues: $0; R&D Expense: $8.4M (-6.7%); SG&A: $4.1M (+64.0%); Net Loss: ($12M) (-6.2%); Loss Per Share: ($0.31) (-10.7%). More news on: Minerva Neurosciences, Healthcare stocks news, Earnings news and commentary, Read more ......
Source: SeekingAlpha
Date: November, 05 2018 09:07
Minerva Neurosciences beats by $0.06
Minerva Neurosciences (NASDAQ: NERV ): Q3 GAAP EPS of -$0.31 beats by $0.06. More news on: Minerva Neurosciences, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 05 2018 07:32
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disor...
Source: GlobeNewswire
Date: November, 05 2018 07:30
Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
Management to host conference call WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it wi...
Source: GlobeNewswire
Date: October, 29 2018 08:30
Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kopin Corporation (NASDAQ:KOPN), MDC Partners Inc. (NASDAQ:MDCA), Dova Ph...
Source: GlobeNewswire
Date: October, 16 2018 08:10
The Verdict On Minerva
"Right now I'm having amnesia and déjà vu at the same time. I think I've forgotten this before." - Steven Wright The other day I got a question from a Seeking Alpha follower on a small biopharma that just went public a few years. Just over a month ago, we published exclusive rese...
Source: SeekingAlpha
Date: October, 09 2018 11:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0810.3510.4510.6010.15110,975
2018-05-176.757.407.556.551494,470
2017-02-0310.8010.8010.8510.509,797
2017-02-0210.4510.7010.8510.158486,001
2017-02-0110.6510.5010.9010.3099,453

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0716,87449,32234.2119Cover
2018-12-066,26117,13136.5478Short
2018-12-0428,79546,26462.2406Short
2018-12-035,18215,34133.7788Cover
2018-11-304,77716,88628.2897Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NERV.


About Minerva Neurosciences, Inc. (NASDAQ: NERV)

Logo for Minerva Neurosciences, Inc. (NASDAQ: NERV)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: NERV)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 24 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 24 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 22 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 12 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 12 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: March, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 21 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: NERV)

      Daily Technical Chart for (NASDAQ: NERV)


      Stay tuned for daily updates and more on (NASDAQ: NERV)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: NERV)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NERV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NERV and does not buy, sell, or trade any shares of NERV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/